Does the media refer more to AQST or KOD?

In the previous week, Aquestive Therapeutics had 2 more articles in the media than Kodiak Sciences. MarketBeat recorded 5 mentions for Aquestive Therapeutics and 3 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 1.38 beat Aquestive Therapeutics' score of 0.39 indicating that Kodiak Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aquestive Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kodiak Sciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PHVS or AQST?

In the previous week, Aquestive Therapeutics had 1 more articles in the media than Pharvaris. MarketBeat recorded 5 mentions for Aquestive Therapeutics and 4 mentions for Pharvaris. Pharvaris' average media sentiment score of 0.55 beat Aquestive Therapeutics' score of 0.39 indicating that Pharvaris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aquestive Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer IMNM or AQST?

In the previous week, Immunome and Immunome both had 5 articles in the media. Aquestive Therapeutics' average media sentiment score of 0.39 beat Immunome's score of 0.35 indicating that Aquestive Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aquestive Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to AQST or AUPH?

In the previous week, Aquestive Therapeutics had 3 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 5 mentions for Aquestive Therapeutics and 2 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 0.96 beat Aquestive Therapeutics' score of 0.39 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aquestive Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aurinia Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Aquestive Therapeutics (AQST) Competitors

$4.16 0.00 (0.00%)

Closing price 06/30/2026 04:00 PM Eastern

Extended Trading

$4.26 +0.09 (+2.28%)

As of 06/30/2026 07:51 PM Eastern

Compare

AQST vs. KOD, NTLA, PHVS, IMNM, and AUPH

Should you buy Aquestive Therapeutics stock or one of its competitors? MarketBeat compares Aquestive Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aquestive Therapeutics include Kodiak Sciences (KOD), Intellia Therapeutics (NTLA), Pharvaris (PHVS), Immunome (IMNM), and Aurinia Pharmaceuticals (AUPH). These companies are all part of the "pharmaceutical products" industry.

How does Aquestive Therapeutics compare to Kodiak Sciences?

Aquestive Therapeutics (NASDAQ:AQST) and Kodiak Sciences (NASDAQ:KOD) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations and media sentiment.

Aquestive Therapeutics has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.21, meaning that its stock price is 121% more volatile than the broader market.

Kodiak Sciences has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -137.08%. Aquestive Therapeutics' return on equity of 0.00% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-137.08%	N/A	-49.33%
Kodiak Sciences	N/A	-253.85%	-81.48%

Aquestive Therapeutics has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than Aquestive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$44.54M	11.72	-$83.78M	-$0.61	N/A
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A

Aquestive Therapeutics currently has a consensus price target of $8.50, suggesting a potential upside of 104.33%. Kodiak Sciences has a consensus price target of $42.14, suggesting a potential upside of 8.17%. Given Aquestive Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Aquestive Therapeutics is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

32.5% of Aquestive Therapeutics shares are owned by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are owned by institutional investors. 6.8% of Aquestive Therapeutics shares are owned by company insiders. Comparatively, 45.9% of Kodiak Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Aquestive Therapeutics had 2 more articles in the media than Kodiak Sciences. MarketBeat recorded 5 mentions for Aquestive Therapeutics and 3 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 1.38 beat Aquestive Therapeutics' score of 0.39 indicating that Kodiak Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aquestive Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kodiak Sciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Aquestive Therapeutics beats Kodiak Sciences on 10 of the 16 factors compared between the two stocks.

How does Aquestive Therapeutics compare to Intellia Therapeutics?

Aquestive Therapeutics (NASDAQ:AQST) and Intellia Therapeutics (NASDAQ:NTLA) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

Aquestive Therapeutics currently has a consensus target price of $8.50, indicating a potential upside of 104.33%. Intellia Therapeutics has a consensus target price of $20.46, indicating a potential upside of 20.90%. Given Aquestive Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Aquestive Therapeutics is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Intellia Therapeutics	3 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.35

32.5% of Aquestive Therapeutics shares are owned by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are owned by institutional investors. 6.8% of Aquestive Therapeutics shares are owned by insiders. Comparatively, 3.5% of Intellia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Aquestive Therapeutics has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market.

Aquestive Therapeutics has higher earnings, but lower revenue than Intellia Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$44.54M	11.72	-$83.78M	-$0.61	N/A
Intellia Therapeutics	$67.67M	34.94	-$412.69M	-$3.54	N/A

Aquestive Therapeutics has a net margin of -137.08% compared to Intellia Therapeutics' net margin of -597.04%. Aquestive Therapeutics' return on equity of 0.00% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-137.08%	N/A	-49.33%
Intellia Therapeutics	-597.04%	-57.47%	-46.24%

In the previous week, Aquestive Therapeutics had 4 more articles in the media than Intellia Therapeutics. MarketBeat recorded 5 mentions for Aquestive Therapeutics and 1 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 1.89 beat Aquestive Therapeutics' score of 0.39 indicating that Intellia Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Aquestive Therapeutics	Neutral
Intellia Therapeutics	Very Positive

Summary

Aquestive Therapeutics beats Intellia Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Aquestive Therapeutics compare to Pharvaris?

Pharvaris (NASDAQ:PHVS) and Aquestive Therapeutics (NASDAQ:AQST) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

Pharvaris has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -137.08%. Aquestive Therapeutics' return on equity of 0.00% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-67.56%	-61.13%
Aquestive Therapeutics	-137.08%	N/A	-49.33%

Pharvaris currently has a consensus price target of $49.64, suggesting a potential upside of 43.54%. Aquestive Therapeutics has a consensus price target of $8.50, suggesting a potential upside of 104.33%. Given Aquestive Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aquestive Therapeutics is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

Pharvaris has a beta of -2.35, suggesting that its share price is 335% less volatile than the broader market. Comparatively, Aquestive Therapeutics has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market.

32.5% of Aquestive Therapeutics shares are held by institutional investors. 6.8% of Aquestive Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Aquestive Therapeutics had 1 more articles in the media than Pharvaris. MarketBeat recorded 5 mentions for Aquestive Therapeutics and 4 mentions for Pharvaris. Pharvaris' average media sentiment score of 0.55 beat Aquestive Therapeutics' score of 0.39 indicating that Pharvaris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aquestive Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aquestive Therapeutics has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Aquestive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A
Aquestive Therapeutics	$44.54M	11.72	-$83.78M	-$0.61	N/A

Summary

Aquestive Therapeutics beats Pharvaris on 13 of the 16 factors compared between the two stocks.

How does Aquestive Therapeutics compare to Immunome?

Immunome (NASDAQ:IMNM) and Aquestive Therapeutics (NASDAQ:AQST) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

Immunome presently has a consensus target price of $33.17, suggesting a potential upside of 56.52%. Aquestive Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 104.33%. Given Aquestive Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aquestive Therapeutics is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

Immunome has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market. Comparatively, Aquestive Therapeutics has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market.

Immunome has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -137.08%. Aquestive Therapeutics' return on equity of 0.00% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-51.15%	-47.32%
Aquestive Therapeutics	-137.08%	N/A	-49.33%

44.6% of Immunome shares are held by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are held by institutional investors. 7.2% of Immunome shares are held by company insiders. Comparatively, 6.8% of Aquestive Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Immunome and Immunome both had 5 articles in the media. Aquestive Therapeutics' average media sentiment score of 0.39 beat Immunome's score of 0.35 indicating that Aquestive Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aquestive Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aquestive Therapeutics has higher revenue and earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than Aquestive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	345.79	-$212.39M	-$2.38	N/A
Aquestive Therapeutics	$44.54M	11.72	-$83.78M	-$0.61	N/A

Summary

Aquestive Therapeutics beats Immunome on 9 of the 16 factors compared between the two stocks.

How does Aquestive Therapeutics compare to Aurinia Pharmaceuticals?

Aquestive Therapeutics (NASDAQ:AQST) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability.

32.5% of Aquestive Therapeutics shares are held by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. 6.8% of Aquestive Therapeutics shares are held by company insiders. Comparatively, 12.2% of Aurinia Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Aquestive Therapeutics had 3 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 5 mentions for Aquestive Therapeutics and 2 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 0.96 beat Aquestive Therapeutics' score of 0.39 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aquestive Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aurinia Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aurinia Pharmaceuticals has higher revenue and earnings than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$44.54M	11.72	-$83.78M	-$0.61	N/A
Aurinia Pharmaceuticals	$283.05M	7.71	$287.20M	$2.17	7.82

Aquestive Therapeutics presently has a consensus price target of $8.50, indicating a potential upside of 104.33%. Aurinia Pharmaceuticals has a consensus price target of $17.25, indicating a potential upside of 1.65%. Given Aquestive Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aquestive Therapeutics is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Aurinia Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Aurinia Pharmaceuticals has a net margin of 99.97% compared to Aquestive Therapeutics' net margin of -137.08%. Aurinia Pharmaceuticals' return on equity of 26.62% beat Aquestive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-137.08%	N/A	-49.33%
Aurinia Pharmaceuticals	99.97%	26.62%	19.65%

Aquestive Therapeutics has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market. Comparatively, Aurinia Pharmaceuticals has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market.

Summary

Aurinia Pharmaceuticals beats Aquestive Therapeutics on 10 of the 17 factors compared between the two stocks.

Get Aquestive Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AQST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AQST vs. The Competition

Export

Metric	Aquestive Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$521.94M	$3.08B	$7.07B	$12.45B
Dividend Yield	N/A	1.86%	2.66%	6.16%
P/E Ratio	-6.82	19.38	27.51	24.87
Price / Sales	11.72	350.27	540.69	102.84
Price / Cash	N/A	57.53	48.53	58.59
Price / Book	-14.86	4.28	11.01	6.54
Net Income	-$83.78M	$64.45M	$3.57B	$336.70M
7 Day Performance	-16.72%	3.22%	2.31%	2.88%
1 Month Performance	4.00%	2.23%	1.38%	0.64%
1 Year Performance	22.35%	34.37%	36.70%	31.34%

Aquestive Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AQST Aquestive Therapeutics	2.8328 of 5 stars	$4.16 flat	$8.50 +104.3%	+25.7%	$521.94M	$44.54M	N/A	160
KOD Kodiak Sciences	1.301 of 5 stars	$36.14 flat	$42.14 +16.6%	+944.5%	$2.26B	N/A	N/A	90	Positive News
NTLA Intellia Therapeutics	2.7924 of 5 stars	$15.67 flat	$20.46 +30.5%	+80.4%	$2.19B	$67.67M	N/A	600
PHVS Pharvaris	3.2283 of 5 stars	$32.80 flat	$49.18 +49.9%	+96.5%	$2.15B	N/A	N/A	30
IMNM Immunome	3.1835 of 5 stars	$18.74 flat	$33.17 +77.0%	+127.8%	$2.12B	$6.94M	N/A	40	Insider Trade High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AQST) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aquestive Therapeutics (AQST) Competitors

AQST vs. KOD, NTLA, PHVS, IMNM, and AUPH

How does Aquestive Therapeutics compare to Kodiak Sciences?

Summary

How does Aquestive Therapeutics compare to Intellia Therapeutics?

Summary

How does Aquestive Therapeutics compare to Pharvaris?

Summary

How does Aquestive Therapeutics compare to Immunome?

Summary

How does Aquestive Therapeutics compare to Aurinia Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQST vs. The Competition

Aquestive Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aquestive Therapeutics (AQST) Competitors

AQST vs. KOD, NTLA, PHVS, IMNM, and AUPH

How does Aquestive Therapeutics compare to Kodiak Sciences?

Which has more risk & volatility, AQST or KOD?

Is AQST or KOD more profitable?

Which has stronger valuation and earnings, AQST or KOD?

Do analysts rate AQST or KOD?

Do insiders & institutionals have more ownership in AQST or KOD?

Does the media refer more to AQST or KOD?

Summary

How does Aquestive Therapeutics compare to Intellia Therapeutics?

Do analysts prefer AQST or NTLA?

Do insiders and institutionals have more ownership in AQST or NTLA?

Which has more risk & volatility, AQST or NTLA?

Which has stronger earnings and valuation, AQST or NTLA?

Is AQST or NTLA more profitable?

Does the media refer more to AQST or NTLA?

Summary

How does Aquestive Therapeutics compare to Pharvaris?

Is PHVS or AQST more profitable?

Do analysts prefer PHVS or AQST?

Which has more volatility & risk, PHVS or AQST?

Do institutionals & insiders have more ownership in PHVS or AQST?

Does the media favor PHVS or AQST?

Which has preferable earnings & valuation, PHVS or AQST?

Summary

How does Aquestive Therapeutics compare to Immunome?

Do analysts recommend IMNM or AQST?

Which has more volatility & risk, IMNM or AQST?

Is IMNM or AQST more profitable?

Do institutionals and insiders have more ownership in IMNM or AQST?

Does the media prefer IMNM or AQST?

Which has preferable earnings and valuation, IMNM or AQST?

Summary

How does Aquestive Therapeutics compare to Aurinia Pharmaceuticals?

Do institutionals & insiders believe in AQST or AUPH?

Does the media refer more to AQST or AUPH?

Which has preferable valuation and earnings, AQST or AUPH?

Do analysts recommend AQST or AUPH?

Is AQST or AUPH more profitable?

Which has more risk and volatility, AQST or AUPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQST vs. The Competition

Aquestive Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools